kabutan

Sumitomo Pharma Co., Ltd., July-September (2Q) Net Income Loss Widens

Wed Oct 30, 2024 1:30 pm JST Earnings

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Earnings Report

Sumitomo Pharma Co., Ltd. <4506> [TSE-P] announced its financial results (based on IFRS) in the afternoon session on October 30th (13:30). The consolidated net loss for the cumulative second quarter of the fiscal year ending March 2025 (April to September) was a reduced loss of 32.2 billion yen (compared to a loss of 67.7 billion yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income/loss for the October to March period (second half) is expected to turn into a profit of 16.2 billion yen (compared to a loss of 247 billion yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the consolidated net loss expanded to a loss of 48.1 billion yen (compared to a loss of 28.8 billion yen in the same period last year). However, the operating profit/loss margin drastically improved from -45.4% in the same period last year to -5.6%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 319,289 -28,915 21,034 -7,283 -18.3 ー Oct 31, 2022 IFRS
Apr - Sep, 2023 152,642 -86,498 -56,127 -67,741 -170.5 ー Oct 31, 2023 IFRS
Apr - Sep, 2024 180,749 -8,179 -32,406 -32,229 -81.1 ー Oct 30, 2024 IFRS
YoY +18.4% +90.5% +42.3% +52.4% +52.4%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance ー ー ー ー － 0 May 14, 2024 IFRS
Apr - Sep, 2024 Results 180,749 -8,179 -32,406 -32,229 -81.1 0 Oct 30, 2024 IFRS
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 161,916 -268,361 -266,987 -247,228 -622.3 0 May 14, 2024 IFRS
Oct - Mar, 2024 Guidance 157,251 8,179 ー 16,229 40.9 0 Oct 30, 2024 IFRS
YoY -2.9% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 555,544 -76,979 -47,920 -74,512 -187.6 21 May 15, 2023 IFRS
Mar, 2024 314,558 -354,859 -323,114 -314,969 -792.8 0 May 14, 2024 IFRS
Mar, 2025 Guidance 338,000 0 ー -16,000 -40.3 0 May 14, 2024 IFRS
YoY +7.5% － － +94.9% +94.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 76,956 -34,931 -25,075 -28,876 -72.7 -45.4 Oct 31, 2023 IFRS
Oct - Dec, 2023 82,386 -31,247 -49,064 -49,967 -125.8 -37.9 Jan 31, 2024 IFRS
Jan - Mar, 2024 79,530 -237,114 -217,923 -197,261 -496.5 -298.1 May 14, 2024 IFRS
Apr - Jun, 2024 90,675 -3,105 17,203 15,937 40.1 -3.4 Jul 31, 2024 IFRS
Jul - Sep, 2024 90,074 -5,074 -49,609 -48,166 -121.2 -5.6 Oct 30, 2024 IFRS
YoY +17.0% +85.5% -97.8% -66.8% -66.8%

Related Articles